The insect vector always bites twice

June 5, 2007

The reality of the threat from vector-borne diseases has been recognized and the problem is prompting research scientists to take a strong interest. Most of these infections, classified as emerging or re-emerging diseases, are linked to ecosystem changes, climatic variations or pressure from human activities. Malaria, sleeping sickness and so on lead to the death of millions of people in the world. African countries are particularly strongly hit. The expansion of Dengue fever and the recent epidemics of Chikungunya and West Nile disease illustrate the trend.

The pathogens responsible for these diseases can be viruses, bacteria or protozoans which are passed on to humans by an arthropod vector, most often a dipteran insect. This becomes infected when it feeds, taking blood from an infected vertebrate host. The pathogenic agent finds conditions to reproduce and proliferate in the vector’s body. In most cases, the parasite moves back into the vector’s salivary glands in order to be transmitted to the human host when the insect bites again to take another blood meal. Morbidity among infected people is therefore associated with the degree of exposure of the subject to insect vector bites.

The vector saliva, which is adapted for blood feeds, plays a prime role in the transmission of the associated diseases. It contains numerous proteins, including immunogenic ones that can modulate or induce a human immune response. Working for the EpiVect programme initiated in 2003, scientists from IRD research unit UR 024 studied this still little known response with the aim of identifying in the arthropod vector saliva the immunogenic proteins responsible. They called on immunological techniques to evaluate qualitatively and quantitatively, in the serum sampled from human populations living in transmission areas, the presence of antibodies targeting specifically these proteins contained in an extract of total saliva of the culprit vector.

This approach, based on the studies of malaria transmission by mosquitoes of the genus Anopheles and human African trypanosomiasis (sleeping sickness) by Glossinia species or tsetse flies, revealed that the antibody response can represent a good indicator of the degree of exposure of humans to bites, which could in the long term allow improved assessment of the risk of transmission of these diseases in a given region.

In Senegal the rate of antisalivary antibodies against Anopheles in young children (under 5 years), the population most exposed to the risk of malaria, appeared to be proportional to the actual degree of exposure, which had been assessed beforehand by standard entomological capture techniques. All the children involved in the study showed a higher level during the period of most intense transmission, in September. The antibody rate proved also to be associated with the risk of occurrence of a malarial attack in the following three months. These antisalivary antibodies consequently seem to be indicators of the risk of malaria in endemic areas, that could be used to improve strategies of prevention and care of young patients in the context of seasonal transmission of the disease.

The objective of the work conducted on human African trypanosomiasis was to analyse the antibody response to identify exactly, in total saliva extract of Glossinia flies, the immunogenic proteins responsible for synthesis of these specific antibodies. The different saliva proteins of four Glossinia species, uninfected, vectors or non-vectors, were separated then put into contact with the serum of individual subjects, infected or uninfected, exposed to bites. Comparison of salivary protein immunogenic profiles obtained showed that they differ depending on the infection status of the subjects (exposed uninfected/infected) and the vector or non-vector status of the Glossinia. Hence, immunogenic proteins specific for two Glossinia species investigated (a 42 kDa protein in G. fuscipes fuscipes, and 50, 55, 65 and 72 kDa proteins in G. morsitans morsitans) could be used to assess specifically the degree of exposure to bites of each of these species.

Starting from immunogenic salivary proteins, simple and effective prevention tools (immuno-tests) can be devised to assess the exposure of human subjects, or be used in endemic areas to evaluate the efficacy of existing vector control strategies, such as the use of impregnated mosquito nets. Analysis of the host-vector relationship, up to now dealt with mainly from the angle of allergic responses to bites or in the search for veterinary vaccines, constitutes now an important research path for new surveillance and prevention strategies.

Source: Institut de Recherche Pour le Développement

Explore further: Researchers cure lung fibrosis in mice with a gene therapy that lengthens telomeres

Related Stories

Researchers cure lung fibrosis in mice with a gene therapy that lengthens telomeres

January 30, 2018
Idiopathic pulmonary fibrosis is a potentially lethal disease associated with the presence of critically short telomeres, currently lacking effective treatment. The Telomere and Telomerase Group at the Spanish National Cancer ...

New technology for accelerated wound healing discovered

February 6, 2018
Researchers at Uppsala University and SLU have found a new way of accelerating wound healing. The technology and the mode of action method published in the highly ranked journal PNAS involves using lactic acid bacteria as ...

Gene therapy restores normal blood glucose levels in mice with type 1 diabetes

January 4, 2018
Type 1 diabetes is a chronic disease in which the immune system attacks and destroys insulin-producing beta cells in the pancreas, resulting in high blood levels of glucose. A study published January 4th in Cell Stem Cell ...

One-dose gene therapy produces clotting factor, safely stops bleeding in hemophilia B patients

December 6, 2017
A team of gene therapy researchers has reported positive results in a phase 1/2 clinical trial for the inherited bleeding disorder hemophilia B. A single intravenous infusion of a novel bioengineered gene therapy treatment ...

Study advances gene therapy for glaucoma

January 16, 2018
While testing genes to treat glaucoma by reducing pressure inside the eye, University of Wisconsin-Madison scientists stumbled onto a problem: They had trouble getting efficient gene delivery to the cells that act like drains ...

First step toward CRISPR cure of Lou Gehrig's disease

December 20, 2017
University of California, Berkeley scientists have for the first time used CRISPR-Cas9 gene editing to disable a defective gene that causes amyotrophic lateral sclerosis, or Lou Gehrig's disease, in mice, extending their ...

Recommended for you

Scientists gain new insight on how antibodies interact with widespread respiratory virus

February 22, 2018
Scientists have found and characterized the activity of four antibodies produced by the human immune system that target an important protein found in respiratory syncytial virus (RSV), according to new research published ...

Study reveals how kidney disease happens

February 22, 2018
Monash researchers have solved a mystery, revealing how certain immune cells work together to instigate autoimmune kidney disease.

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.